Envista Holdings Corp (NVST) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Envista Holdings Corp Do?
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands. This segment also offers software packages, which include DTX Studio Implant for treatment planning of dental implants; TX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic to store and access a various clinical patient images. The company's Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, sensors, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California. Envista Holdings Corp (NVST) is classified as a mid-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Amir A. Aghdaei and employs approximately 12,700 people. With a market capitalization of $4.2B, NVST is one of the notable companies in the Healthcare sector.
Envista Holdings Corp (NVST) Stock Rating — Hold (April 2026)
As of April 2026, Envista Holdings Corp receives a Hold rating with a composite score of 48.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.NVST ranks #1,196 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Envista Holdings Corp ranks #88 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
NVST Stock Price and 52-Week Range
Envista Holdings Corp (NVST) currently trades at $26.39. The stock lost $0.28 (1.0%) in the most recent trading session. The 52-week high for NVST is $30.42, which means the stock is currently trading -13.2% from its annual peak. The 52-week low is $14.22, putting the stock 85.6% above its annual trough. Recent trading volume was 1.4M shares, reflecting moderate market activity.
Is NVST Overvalued or Undervalued? — Valuation Analysis
Envista Holdings Corp (NVST) carries a value factor score of 53/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 185.85x, compared to the Healthcare sector average of 23.63x — a premium of 687%. The price-to-book ratio stands at 1.33x, versus the sector average of 2.75x. The price-to-sales ratio is 1.61x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, NVST trades at 34.16x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 23.56x.
Overall, NVST's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Envista Holdings Corp Profitability — ROE, Margins, and Quality Score
Envista Holdings Corp (NVST) earns a quality factor score of 44/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 0.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 0.4% versus the sector average of -33.1%.
On a margin basis, Envista Holdings Corp reports gross margins of 54.2%, compared to 71.5% for the sector. The operating margin is 6.3% (sector: -66.1%). Net profit margin stands at 0.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 5.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
NVST Debt, Balance Sheet, and Financial Health
Envista Holdings Corp has a debt-to-equity ratio of 47.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.38x, indicating strong short-term liquidity. Total debt on the balance sheet is $1.45B. Cash and equivalents stand at $1.13B.
NVST has a beta of 0.93, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Envista Holdings Corp is 59/100, reflecting average volatility within the normal range for its sector.
Envista Holdings Corp Revenue and Earnings History — Quarterly Trend
In TTM 2026, Envista Holdings Corp reported revenue of $2.57B and earnings per share (EPS) of $0.28. Net income for the quarter was $22M. Gross margin was 54.2%. Operating income came in at $164M.
In FY 2025, Envista Holdings Corp reported revenue of $2.72B and earnings per share (EPS) of $0.28. Net income for the quarter was $47M. Gross margin was 54.7%. Revenue grew 8.3% year-over-year compared to FY 2024. Operating income came in at $216M.
In Q3 2025, Envista Holdings Corp reported revenue of $670M and earnings per share (EPS) of $-0.18. Net income for the quarter was $-30M. Gross margin was 55.3%. Revenue grew 11.5% year-over-year compared to Q3 2024. Operating income came in at $58M.
In Q2 2025, Envista Holdings Corp reported revenue of $682M and earnings per share (EPS) of $0.16. Net income for the quarter was $26M. Gross margin was 54.2%. Revenue grew 7.7% year-over-year compared to Q2 2024. Operating income came in at $46M.
Over the past 8 quarters, Envista Holdings Corp has demonstrated a growth trajectory, with revenue expanding from $633M to $2.57B. Investors analyzing NVST stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
NVST Dividend Yield and Income Analysis
Envista Holdings Corp (NVST) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
NVST Momentum and Technical Analysis Profile
Envista Holdings Corp (NVST) has a momentum factor score of 66/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 31/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 22/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
NVST vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Envista Holdings Corp (NVST) ranks #88 out of 838 stocks based on the Blank Capital composite score. This places NVST in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing NVST against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NVST vs S&P 500 (SPY) comparison to assess how Envista Holdings Corp stacks up against the broader market across all factor dimensions.
NVST Next Earnings Date
No upcoming earnings date has been announced for Envista Holdings Corp (NVST) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy NVST? — Investment Thesis Summary
Envista Holdings Corp presents a balanced picture with arguments on both sides. Price momentum is positive at 66/100, suggesting the trend favors buyers.
In summary, Envista Holdings Corp (NVST) earns a Hold rating with a composite score of 48.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NVST stock.
Related Resources for NVST Investors
Explore more research and tools: NVST vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NVST head-to-head with peers: NVST vs AZN, NVST vs SLGL, NVST vs VMD.